 Nitrogen Mustard Compounds
"Nitrogen Mustard Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
| Descriptor ID |
D009588
|
| MeSH Number(s) |
D02.455.526.728.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitrogen Mustard Compounds".
Below are MeSH descriptors whose meaning is more specific than "Nitrogen Mustard Compounds".
This graph shows the total number of publications written about "Nitrogen Mustard Compounds" by people in this website by year, and whether "Nitrogen Mustard Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Nitrogen Mustard Compounds" by people in Profiles.
-
Sekela ME, Snyder EL, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, Beaver TM, Pelletier JPR, Gorham JD, McNeil JS, Sniecinski RM, Pearl RG, Nuttall GA, Sarode R, Reece TB, Benjamin RJ. Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial. Anesthesiology. 2025 Nov 01; 143(5):1196-1210.
-
Kishimoto S, Crooks DR, Yasunori O, Kota Y, Yamamoto K, Linehan WM, Levine M, Krishna MC, Brender JR. Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug. Free Radic Biol Med. 2024 Sep; 222:579-587.
-
Snyder EL, Sekela ME, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, Beaver TM, Pelletier JPR, Gorham JD, McNeil JS, Sniecinski RM, Pearl RG, Nuttall GA, Sarode R, Reece TB, Kaplan A, Davenport RD, Ipe TS, Benharash P, Lopez-Plaza I, Gammon RR, Sadler P, Pitman JP, Liu K, Bentow S, Corash L, Mufti N, Varrone J, Benjamin RJ. Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial. Trials. 2023 Dec 11; 24(1):799.
-
Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug; 170(3):336-48.
-
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 08; 123(19):2944-52.
-
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):831-7.
-
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
-
Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion. 2011 Nov; 51(11):2367-76.
-
Glode AE, Jarkowski A. Bendamustine: a new treatment option for chronic lymphocytic leukemia. Pharmacotherapy. 2009 Nov; 29(11):1375-84.
-
Worthen GS, Haslett C, Rees AJ, Gumbay RS, Henson JE, Henson PM. Neutrophil-mediated pulmonary vascular injury. Synergistic effect of trace amounts of lipopolysaccharide and neutrophil stimuli on vascular permeability and neutrophil sequestration in the lung. Am Rev Respir Dis. 1987 Jul; 136(1):19-28.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|